The first psychedelic drug launch, if it comes, will be run slowly on purpose. Compass Pathways chief executive Kabir Nath told the STAT Summit in Boston on October 14 that the company expects to complete its rolling submission to the FDA this quarter for COMP360, its synthetic psilocybin for treatment resistant depression, and is aiming to launch early next year if regulators approve it. His argument was that a bad early experience for a patient or a provider would damage not only Compass but the entire field, so the company will sequence rollout behind training and site readiness rather than maximize early volume.
The operating model is unlike a conventional antidepressant launch. Treatment involves a roughly six hour supervised administration session. Nath said the company expects an FDA risk evaluation and mitigation strategy to apply, and that it is investing in provider training ahead of any approval. In the company’s Phase 3 program, about a quarter of patients had a clinically meaningful response after a single administration, rising to about 40 percent after a second dose three weeks later, with benefits in responders reported to last as long as a year after two or three administrations. Those are company stated figures from its trials, presented by its chief executive, and the FDA review now in progress is the test of them.
The commercial read is about capacity, not demand. A supervised, hours long, clinic based therapy competes for the same treatment center infrastructure as other interventional psychiatry, and reimbursement, site certification and therapist time will set the real launch curve. Compass is effectively conceding that in advance and pricing its story on durability of response per patient treated rather than prescription volume. Investors in the psychedelics sector, which has had no approved product and one prominent FDA rejection in the Lykos MDMA decision, will read the filing completion this quarter as the next hard milestone.